Shares of Bristol Myers Squibb Co. BMY shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. Net income rose to $2.07 billion, or 99 cents a share, from $1.42 billion, or 66 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.75 missed the FactSet consensus of $1.98. Revenue fell 5.
2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. Net income rose to $2.07 billion, or 99 cents a share, from $1.42 billion, or 66 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.75 missed the FactSet consensus of $1.98. Revenue fell 5.6% to $11.
Nederland Laatste Nieuws, Nederland Headlines
Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.
Alphabet stock jumps on earnings while Microsoft shares dip, and other stocks on the moveAlphabet, Microsoft, Dish Networks and PacWest Bancorp are among the stocks in the spotlight.
Bron: MarketWatch - 🏆 3. / 97 Lees verder »